. Author manuscript; available in PMC: 2013 Dec 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2012 Jul 2;18(12):1851–1858. doi: 10.1016/j.bbmt.2012.06.016

Table 1.

Baseline Patient and Unit Characteristics

	13 Patients Transplanted
Race:
White	10 (76.9%)
Asian	1 (7.7%)
Other	2 (15.4%)
Ethnicity: Hispanic	4 (30.8%)
Age at Transplantation (years): Median (Range)	39 (25–67)
Primary Disease
MDS	2(15.4%)
Aplastic Anemia	2(15.4%)
Hodgkin’s Disease	1(7.7%)
Chronic lymphocytic leukemia	1(7.7%)
Acute myeloid leukemia	5(38.5%)
Acute lymphoblastic leukemia	2(15.4%)
ECOG Performance Status at Transplantation
0-	4(30.8%)
1-	8(61.5%)
2-	1(7.7%)
HLA Match: Recipient to Unit 1 and Unit 2
4/6, 4/6	10 (76.9%)
4/6, 5/6	1 (7.7%)
5/6, 5/6	2 (15.4%)
HLA Match: Unit 1 to Unit 2
4/6	10(76.9%)
5/6	3(23.1%)
Combined Post-thaw Cell Doses
TNC dose×10⁷/kg	4.2 (3.4–6.6)
CD34 dose×10⁵/kg	2.1(0.4–9.0)
Conditioning Regimen
Myeloablative	9 (69.2%)
Reduced Intensity	4 (30.8%)

Notes: N and (%) or median (minimum-maximum) are displayed. ECOG=Eastern Cooperative Oncology Group, TNC=Total nucleated cell